Company news
Ocular Therapeutix, Inc. (NASDAQ:OCUL) news
Every Ocular Therapeutix, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Ocular Therapeutix : trade; Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 13, 2026
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emergin...
August 10, 2026
Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights
August 3, 2026
Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026
June 17, 2026
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
June 9, 2026
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026
June 4, 2026
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
May 29, 2026
Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
May 5, 2026
Ocular Therapeutix Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI in Wet AMD
April 30, 2026
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD
April 29, 2026
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026
April 28, 2026
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences
April 27, 2026
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
April 22, 2026
Ocular Therapeutix Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
April 15, 2026
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD
April 13, 2026
Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April
April 1, 2026
Ocular Therapeutix™ to Participate in March Investor Conferences
February 24, 2026
Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Present...
February 23, 2026
Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD
February 17, 2026
Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026
February 13, 2026
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
February 5, 2026
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 23, 2026
Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer
January 21, 2026
Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD
December 8, 2025
Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR
November 24, 2025
Ocular Therapeutix™ to Participate in November and December Investor Conferences
November 12, 2025
Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R
November 4, 2025
Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights
November 4, 2025
Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025
October 28, 2025
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
October 7, 2025
Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to P...
September 30, 2025
Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock
September 30, 2025
Ocular Therapeutix™ to Host Investor Day on September 30, 2025
September 8, 2025
Ocular Therapeutix™ to Participate in September Investor and Scientific Conferences
August 27, 2025
Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR
August 12, 2025
Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights
August 5, 2025
Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025
July 29, 2025
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
June 26, 2025
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025
June 16, 2025
Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macul...
May 28, 2025
Ocular Therapeutix™ to Participate in Upcoming Investor Conferences
May 14, 2025
Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights
May 5, 2025
Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences
April 29, 2025
Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025
April 28, 2025
Ocular Therapeutix™ to Participate in Two Investor Conferences in April
March 31, 2025
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights
March 3, 2025
Ocular Therapeutix™ to Present at Two Investor Conferences in March
February 25, 2025
Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025
February 24, 2025
Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting
February 3, 2025
Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR
January 14, 2025